Eligible participants were aged 13 years or older and had a confirmed diagnosis of SMA based on homozygous deletion of exon 7 or compound heterozygosity for pathogenic mutations in the SMN1 gene. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.